Onychomycosis (and II): Diagnosis and treatment;Onicomicosis (y II): Diagnostico y tratamiento

Actas Dermo-Sifiliograficas

Volumn 87, Issue 12, 1996, Pages 659-673

  Velez Garcia Nieto, Antonio ^a,c   Linares Sicilia, Ma Jose ^b   Fernandez Roldan, Jose Carlos ^a   Casal Roman, Manuel ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c Centro de Salud Guzmán El Bueno   (Spain)

Author keywords

amorolfine; fluconazole; itraconazole; onychomycosis; terbinafin

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROXOLAMINE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; PROPYLENE GLYCOL; TERBINAFINE; TIOCONAZOLE;

HUMAN; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0030482332     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. André J, Achten G. Onychomycosis. Int J Dermatol 1987; 26: 481-490.
2. Castillo V, Castillo M. Técnicas de diagnóstico en micología cutánea. Piel 1988; 3: 44-49
3. Hay RJ, Baran R, Haneke E. Fungal (onychomychosis) and other infections involving the nail apparatus. En: Baran R, Dawber RPR. Diseases of the Nails and their Management, 2nd ed. Oxford: Blackwell Scientific Publications, 1994; 97-134.
4. Del Palacio-Hernanz A, García-Bravo M. Onicomicosis. En: Torres-Rodríguez JM et al. Micologia Médica. Barcelona: Masson, SA, 1993; 65-73.
5. Torres-Rodríguez JM. El laboratorio de micología médica. En: Torres-Rodríguez JM et al. Micología Médica. Barcelona: Masson, SA, 1993; 11-22.
6. Crespo Erchiga V. El examen directo. En: Crespo Erchiga V (ed): Dermatomicosis. Diagnóstico de Laboratorio. Madrid: International Marketing and Communications, SA, 1995; 13-26.
7. Elewski BE, Greer DL. Hendersonula toruloidea and Scytalidium hyalinum. Review and update. Arch Dermatol 1991; 127: 1041-1044.
8. Davies RR. Mycological tests and onychomycosis. J Clin Path 1968, 21: 729-730.
9. Rubio Calvo D, Rezusta López A, Grasa Jordán MP, Salvo Gonzalo S, Gil Tomás J, Alejandre Agustin MC, Bueno Ibáñez MR, Gómez-Lus R. Micopatología ungueal. Estudio micológico de onicomicosis y tinea unguium. Rev Iber Micol 1988; 5: 90-99.
10. McAleer R. Fungal infections of the nails in Western Australia. Mycopathologia 1981; 73: 115-120.
11. Clayton YM. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol 1992; 17 (suppl 1): 37-40.
12. Willemsen M. Changing patterns in superficial infections: focus on onychomycosis. J Eur Acad Dermatol Venereol 1993; 2 (suppl 1):S6-S11.
13. Zaias N. Onychomycosis. En: Zaias N. The Nail in Health and Disease, 2nd ed. Norwalk: Appleton & Lange, 1990; 87-105.
14. English MP. Nails and fungi. Br J Dermatol 1976; 94: 697-701.
15. Liu HN, Lee DD, Wong CK. KONCPA: a new method for diagnosing tinea unguium. Dermatology 1993; 187: 166-168.
16. Haley L, Daniel CR III. Fungal infections. En: Scher RK, Daniel CR III. Nails: Therapy, Diagnosis, Surgery. Philadelphia: WB Saunders Company, 1990; 106-119.
17. Crespo Erchiga V. Los cultivos. En: Crespo Erchiga V (ed): Dermatomicosis. Diagnóstico de Laboratorio. Madrid: International Marketing and Communications, SA, 1995; 29-44.
18. Midgley G, Moore MK. Identificación de dermatofitos. En: Crespo Erchiga V (ed): Dermatomicosis. Diagnóstico de Laboratorio. Madrid: International Marketing and Communications, SA, 1995; 47-64.
19. Stary A, Crespo V. Identificación de levaduras. En: Crespo Erchiga V (ed): Dermatomicosis. Diagnóstico de Laboratorio. Madrid: International Marketing and Communications, SA, 1995; 67-86.
20. Crespo V. Identificación de contaminantes. En: Crespo Erchiga V (ed): Dermatomicosis. Diagnóstico de Laboratorio. Madrid: International Marketing and Communications, SA, 1995; 89-118.
21. Sagher F. Histologic examinations of fungous infections of the nails. J Invest Dermatol 1948; 11: 337-354.
22. Scher RK, Ackerman AB. Subtle clues to diagnosis from biopsies of nails. Am J Dermatopathol 1980; 2: 55-57.
23. Suárez SM, Silvers DN, Scher RK, Pearlstein HH, Auerbach R. Histologic evaluation of nail clippings for diagnosing onychomycosis. Arch Dermatol 1991; 127: 1517-1519.
24. Daniel CR. The diagnosis of nail fungal infection. Arch Dermatol 1991; 127: 1566-1567.
25. Piérard GE, Arrese JE, Pierre S, Bertrand C, Corcuff P, Levêque JL, Piérard-Franchimonts C. Diagnostic microscopique des onychomychoses. Ann Derm Venereol 1994; 121: 25-29.
26. Goettmann S, Grossin M. La biopsie unguéale. Techniques et indications diagnostiques. Ann Pathol 1992; 12: 295-302.
27. Arrese Estrada J, Stynen D, Goris A, Piérard GE. Identification immunohistochimique des Aspegillus par 1. anticorps monoclonal EB-A1. Ann Pathol 1990; 10: 198-200.
28. Arrese Estrada J, Slynen D, Van Cutsem J, Piérard-Franchimont C, Piérard GE. Immunohistochemical identification of Penicillium marneffei by monoclonal antibody. Int J Dermatol 1992; 31: 410-412.
29. Arresc JE, Greimers R, Piérard GE. Las onicomicosis. De la técnica de KOH a la biología molecular. Med Cutan Iber Lat Am 1994; 22: 37-42.
30. Grigoriu D, Grigoriu A. Les onychomycoses. Rev Med Suisse Romande 1975; 95: 839-849.
31. Baran R, Badillet G. Un dermatophyte unguéal est-il nécessairement pathogène? Ann Dermatol Venereol 1983; 110: 629-631.
32. Baran R, Badillet G. Primary onycholysis of the big toenail: a review of 113 cases. Br J Dermatol 1982; 106: 529-534.
33. Zaias N. Psoriasis of the nail. En: Zaias N. The Nail in Health and Disease, 2nd ed. Norwalk: Appleton & Lange, 1990; 137-151.
34. Odds FC. Morphogenesis in Candida, with special reference to C. albicans. En: Odds FC. Candida and Candidosis. A review and bibliography, 2nd ed. London: Baillière Tindal, 1988; 42-59.
35. Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol 1993; 129: 101-109.
36. Clayton YM, Hay RJ. Epidemiology of fungal skin and nail disease: roundtable discussion held at Dermatology 2000, Vienna, 17 May 1993. Br J Dermatol 1994; 130 (suppl 43): 9-11.
37. Hay RJ, Baran R, Moore MK, Wilkinson JD. Candida onvchomycosis - an evaluation of the role of Candida species in nail disease. Br J Dermatol 1988; 118: 8-58.
38. Piérard GE. In vivo confocal microscopy: a new paradigm in dermatology. Dermatology 1993; 186: 4-5.
39. Hutter KJ, Eipel HE. Simultaneous measurements of DNA and protein content of microorganism by flow cytometry. Eur J Appl Microbiol 1979; 6: 223-231.
40. Korting HC, Schäfer-Korting M. Is tinea unguium still widely incurable? Arch Dermatol 1992; 128: 243-248.
41. Del Palacio A, Cuétara MS, Castejón A. Avances en el tratamiento de onicomicosis y dermatofitosis. Medicine 1994; 6: 24-36.
42. Hay RJ. Onychomychosis. Agents of choice. Dermatol Clin 1993; 11: 161-169.
43. Haneke E. Fungal infections of the nail: nail disease. Semin Dermatol 1991; 10: 41-51.
44. Sánchez Carazo JL, Millán Parrilla F. Tratamiento actual de las onicomicosis. Piel 1991; 6: 489-493.
45. Farber E, South DA. Urea ointment in the nonsurgical avulsion of nail dystrophies. Cutis 1978; 22: 689-693.
46. South DA, Farber E. Urea ointment in nonsurgical avulsion of nail dystrophies, reappraisal. Cutis 1980; 21: 609-612.
47. White MI, Clayton YM. The treatment of fungus and yeast infections of nails by the method of chemical removal. Clin Exp Dermatol 1982; 7: 273-276.
48. Dorn M, Kienitz T, Ryckmanns F. Onychomychosis: experience with non-traumatic nail avulsion. Hautartz 1980; 31: 30-34.
49. Buselmeier FJ. Combination urea and salicylic acid ointment nail avulsion in one dystrophic nail: follow-up observation. Cutis 1980; 25: 393-396.
50. Stone LA, Lindfield EM, Robertson S. Atlas de técnicas de enfermería en Dermatología. Barcelona: Ediciones Doyma, 1990; 40-41.
51. Rollman O. Treatment of onychomycosis by partial nail avulsion and topical miconazole. Dermatologica 1982; 165: 54-61.
52. Hay RJ, Roberts D, Doherty VR, Richardson MD, Midgley G. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 17: 164-167.
53. Hardjoko FS, Widyauto S, Singgih I, Susilo J. Treatment of onychomycosis with a bifonazole-urea combination. Mycoses 1990; 33: 167-171.
54. Achten G, Degreef H, Dockx P. Treatment of onychomycosis with a solution of miconazole 2% in alcohol. Mykosen 1977; 20: 251-260.
55. Hay RJ, Mackie RM, Clayton YM. Tioconazole (28%) nail solution: an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 152-157.
56. De la Barreda F, Arenas R, Domínguez Soto L. Tioconazol a 28% en barniz: tratamiento de 20 casos de onicomicosis. Med Cutan Iber Lat Am 1994; 22: 147-150.
57. Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175-177.
58. Stubb S, Heikkila H, Reitaino S, Forstrom L. Contact allergy to tioconazole. Contact Dermalitis 1992; 26: 155-158.
59. Fargemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol-urea-lactic acid solution. Mycoses 1989; 32: 536-540.
60. Ceschin-Roques CG, Hanel H, Pruja-Bougaret SM et al. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin. Skin Pharmacol 1991; 4: 89-94.
61. Torres-Rodríguez JM, Madrenys N, Sala J, Pérez ML. Tratamiento tópico de las micosis ungueales con ciclopiroxolamina al 1%. Resultados clínicos y micológicos. Actas Dermosifiliogr 1990; 81: 458-462.
62. Rollman O, Johansson S. Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopirx olamine. Acta Derm Venereol (Stockh) 1987; 67: 506-510.
63. Polak A. Preclinical data and mode of action of amorolfine. Dermatology 1992; 184 (suppl): 3-7
64. Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (and overview) Clin Exp Dermatol 1992; 17 (suppl 1): 61-70
65. Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology 1992; 182 (suppl): 21-24.
66. Williams DI, Marten RH, Sarkany I. Oral treatment of ringworm with griseofulvin. Lancet 1958; 2: 1212-1213.
67. Nimni ME, Ertl D, Oakes RA. Distribution of griseofulvin in the rat: comparasion of the oral and topical route of administration. J Pharm Pharmarol 1990; 42: 729-731.
68. Macasaet EN. Pert P. Topical (1%) solution of griseofulvin in the treatment of tinea torporis. Br J Dermatol 1991; 124: 110-111.
69. Atkinson RM, Bedford C, Child KJ, Tomich EG. Human blood griseofulvin levels from different dosage schedules. Antibiot Chemother 1962; 12: 225-231.
70. Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in the stratum corneum: study after oral administration in man. Arch Dermatol 1972; 106: 344-348.
71. Crounse RG. Human pharmacology of griseofulvin: the effect of fat intake on gastrointestinal absortion. J Invest Dermatol 1961; 37: 529-533.
72. Meinhof W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol 1993; 29: S37-S41.
73. Piérard GE, Arrese-Estrada J, Piérard-Franchimont C. Treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 1993; 29: S41-S45.
74. Hargrcaves GK. The treatment of onychomycosis with griseofulvin. Br J Dermatol 1960; 72: 358-364.
75. Stevenson CJ, Djavahiszwili N. Chronic ringworm of the nails: long-term treatment with griseofulvin. Lancet 1961; 1:373-374.
76. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. Br Med J 1967; 3: 464-468.
77. Artis WM, Odle BM, Jones HE. Griseofulvin resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981; 113: 16-20.
78. Figueiredo A, Ruas E. Progresos en terapéutica antifúngica. Los nuevos triazoles: itraconazol y fluconazol. Piel 1993; 8: 425-428.
79. Elewski B. Mechanisms of action of systemic antifungals agents. J Am Acad Dermatol 1993; 28: S28-S34.
80. Daneshment TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14: 13-34.
81. Van Cutsem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen PAJ. The antiinflamatory effects of ketoconazole. A comparative study with hidrocortisone acetate in a model using living and killed Staphylococcus aureus of the skin of guinea-pigs. J Am Acad Dermatol 1991; 25: 257-261.
82. Rosenberg EW, Belew PW. Improvement of psoriasis of the scalp with ketoconazole. Arch Dermatol 1982; 118: 370-371.
83. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317: 812-818.
84. Janssen PAJ, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med 1983; 13: 80-85.
85. Lesher JK, Smith G Jr. Antifungals agents in dermatology. J Am Acad Dermatol 1987; 17: 383-394.
86. Robertson MH, Hanifin JM, Parker F. Oral therapy with ketoconazole for dermatophyte infections unresponsive to griseofulvin. Rev Infect Dis 1980; 2: 578-581.
87. Galimberti R, Negroni R, Iglesia de Elias Costa MR, Casala AM. The activity of ketoconazole in the treatment of onychomycosis. Rev Infect Dis 1980; 2: 596-598.
88. Robertson MH, Rich P, Parker F, Hanifin JM. Ketoconazole in griseofulvin-resistant dermatophytosis. J Am Acad Dermatol 1982; 6: 224-229.
89. Tucker RM, Denning DW, Arathoon EG, Rinaldi MG, Stevens DA. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990; 23: 593-601.
90. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23: 607-614.
91. Restrepo A, Robledo J, Gómez I, Tabares AM, Gutiérrez R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis Arch Dermatol 1986; 122: 413-417.
92. Saul A, Bonifaz A. Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol 1990; 23: 554-558.
93. Blatchford NR. Treatment of oral candidiasis with itraconazole: a review. J Am Acad Dermatol 1990; 23: 565-567.
94. Delescluse J. Itraconazole in tinea versicolor. J Am Acad Dermatol 1990; 23: 551-554.
95. Wishart JM. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol 1987; 17: 220-223.
96. Boelaert J, Schurgers M, Matthvs E, Daneels R, Van Peer A. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1988; 32: 1595-1597.
97. Cauwenbergh G, DeGreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-268.
98. Willemsen M, De Doncker P, Willems J, Woestenborghs R, Van de Velde V, Heykants J, Van Cutsem J, Cauwenbergh G, Roseeuw D. Posttreatment itraconazol levels in the nail. J Am Acad Dermatol 1992; 26: 731-735.
99. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-933.
100. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993; 29: S50-S54.
101. Rex J. Itraconazole-digoxin interaction (letter). Ann Inter Med 1992; 116: 525.
102. Díaz-Maroto S. Itraconazol: un nuevo antifúngico oral. Revista de la Sociedad Española de Farmacia Hospitalaria 1990; 14: 163-168
103. Hay RJ, Clayton YM, Moore MK, Midgley G. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359-366.
104. Degreef H. Onychomycosis. Br J Clin Pract 1990; 44 (suppl 2): 91-97.
105. Hanifin JM, Tofte SJ. Itraconazole therapy for recalcitrant dermatophyte infections. J Am Acad Dermatol 1988; 18: 1077-1080.
106. Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis: open and double-blind studies. Acta Derm Venereol (Stockh) 1990; 70: 137-140.
107. Roseeuw D, De Doncker PD. New therapeutic concepts for the treatment of onychomycosis. J Eur Acad Dermatol Venereol 1993; 2: 34-38.
108. De Doncker P, Van Daele M, Decroix J, Dockx P, Roseeuw D, Heykants B, Roelant D, Woestenborghs R, Van Cutsem J, Cauwenberg G. Intermitten therapy with itraconazole produces persistent high levels in the nail and is effective in onychomycosis. 51th Annual Meeting American Academy Dermatology. San Francisco, December 1992, Poster 69.
109. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-917.
110. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990; 12 (suppl): S327-S333.
111. DeWit S, Clumeck N. Fluconazole in the treatment of fungal infections associated with AIDS. Infection 1989; 17: 121-123.
112. Haneke E. Fluconazole levels in human epidermis and blister fluid. Br J Dermatol 1990; 123: 273-277.
113. Montero-Gey M, Perera A. Therapy with fluconazole for linea carporis, tinea cruris and tinea pedis. Clin Infect Dis 1992; 14: 77-81.
114. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 128: 909-910.
115. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3: 115-117.
116. Balfour JA, Foulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-284.
117. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994; 31: S78-S81.
118. Ryder NS. The mechanism of action of terbinafine. Clin Exp Dermatol 1989; 14: 98-100.
119. Birbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol 1990; 23: 782-785.
120. Faergemann J, Zehender H, Jones T, Maiback I. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol (Stockh) 1990; 71: 322-326.
121. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126 (suppl 39): 28-32.
122. Figueiredo A. Farmacología clínica de terbinafina. Piel 1993; 8: 473-479.
123. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126 (suppl 39): 61-69.
124. Juhlin L. Loss of taste and terbinafine (letter). Lancet 1992; 339: 1483.
125. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 1992; 126 (suppl 39): 51-55.
126. Goodfield MJD, Rowell NR, Forster RA, Evans EGV, Raven A. Treatment of dermatophyte infection of the finger and toe nails with terbinafine (SF 86-327, Lamisil) an orally active fungicidal agent. Br J Dermatol 1989; 121: 753-757.
127. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14: 120-123.
128. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126 (suppl 39): 40-46.
129. Van der Schroeff JG, Cirkel PKS, Crijns MB, Van Dijk TJA, Govaert FJ, Groeneweg DA. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 (suppl 39): 36-39.
130. Munron CS, Rees JL, Shuster S. The unexpectedly rapide response of fungal nail infection to short duration therapy. Acta Derm Venereol (Stockh) 1992; 26: 731-735.
131. Nolting S, Biaugtigam M, Weidinger G Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994, 130 (suppl 43): 16-21.
132. Roberts DT, Richardson MD, Dwyer PK. Terbinafine in chronic paronychia and Candida onychomychosis. J Dermatol Treat 1992; 3 (suppl): 39-42.
133. Chren MM. Costs of therapy for dermatophyte infections. J Am Acad Dermatol 1994; 31: S103-S106.
134. Arikian SR, Einarson TR, Robelt-Xguyen G, Schubert F. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 (suppl 43): 35-44.
135. Zaias N, Drachman D. A method for the determination of drug effectiveness in onychomycosis. J Am Acad Dermatol 1983; 9: 912-919.